218 related articles for article (PubMed ID: 10687980)
1. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors.
Morris MJ; Bosl GJ
J Urol; 2000 Mar; 163(3):796-801. PubMed ID: 10687980
[TBL] [Abstract][Full Text] [Related]
2. Re: Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors.
Schatte EC; Lerner SP
J Urol; 2000 Nov; 164(5):1670. PubMed ID: 11203071
[No Abstract] [Full Text] [Related]
3. [The role of tumor markers in the treatment of germ cell tumor].
Niwakawa M; Tobisu K
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1159-65. PubMed ID: 11525037
[TBL] [Abstract][Full Text] [Related]
4. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.
Saxman SB; Nichols CR; Foster RS; Messemer JE; Donohue JP; Einhorn LH
J Urol; 1996 Feb; 155(2):587-9. PubMed ID: 8558665
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of tumor markers in the treatment of germ cell tumors].
Germá Lluch JR; García del Muro X; Galán MC
Arch Esp Urol; 2000; 53(6):460-8. PubMed ID: 11002513
[TBL] [Abstract][Full Text] [Related]
6. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
Beck SD; Patel MI; Sheinfeld J
J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
[TBL] [Abstract][Full Text] [Related]
7. [Testis cancer markers. Clinical use].
Salesi N; Di Cocco B; Alghisi F; Calabretta F; Bossone G
Minerva Med; 2002 Oct; 93(5):365-9. PubMed ID: 12410169
[TBL] [Abstract][Full Text] [Related]
8. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
10. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
Fizazi K; Culine S; Kramar A; Amato RJ; Bouzy J; Chen I; Droz JP; Logothetis CJ
J Clin Oncol; 2004 Oct; 22(19):3868-76. PubMed ID: 15302906
[TBL] [Abstract][Full Text] [Related]
11. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
12. Tumor markers in patients with non-seminomatous germ cell tumors of the testis.
Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
Oncodev Biol Med; 1981; 2(1-2):117-28. PubMed ID: 6170952
[TBL] [Abstract][Full Text] [Related]
13. Serum markers in germ cell neoplasms.
Bartlett NL; Freiha FS; Torti FM
Hematol Oncol Clin North Am; 1991 Dec; 5(6):1245-60. PubMed ID: 1723408
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of alpha 1-fetoprotein and beta-human chorionic gonadotropin in infancy and childhood.
Schneider DT; Calaminus G; Göbel U
Pediatr Hematol Oncol; 2001; 18(1):11-26. PubMed ID: 11205836
[TBL] [Abstract][Full Text] [Related]
15. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
Toner GC; Geller NL; Tan C; Nisselbaum J; Bosl GJ
Cancer Res; 1990 Sep; 50(18):5904-10. PubMed ID: 1697503
[TBL] [Abstract][Full Text] [Related]
16. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
[TBL] [Abstract][Full Text] [Related]
17. Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use.
Toner GC
J Clin Oncol; 2004 Oct; 22(19):3842-5. PubMed ID: 15302908
[No Abstract] [Full Text] [Related]
18. Detection of germ-cell tumor cells in the peripheral blood by nested reverse transcription-polymerase chain reaction for alpha-fetoprotein-messenger RNA and beta human chorionic gonadotropin-messenger RNA.
Hautkappe AL; Lu M; Mueller H; Bex A; Harstrick A; Roggendorf M; Ruebben H
Cancer Res; 2000 Jun; 60(12):3170-4. PubMed ID: 10866307
[TBL] [Abstract][Full Text] [Related]
19. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
Christensen TB; Engbaek F; Marqversen J; Nielsen SI; Kamby C; von der Maase H
Br J Cancer; 1999 Jul; 80(10):1577-81. PubMed ID: 10408402
[TBL] [Abstract][Full Text] [Related]
20. Serum alpha-fetoprotein and human chorionic gonadotropin in the management of testicular tumors.
Lange PH
Natl Cancer Inst Monogr; 1978 Dec; (49):215-7. PubMed ID: 86163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
